Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach
Status: | Recruiting |
---|---|
Conditions: | Neurology, Neurology, Multiple Sclerosis |
Therapuetic Areas: | Neurology, Other |
Healthy: | No |
Age Range: | 18 - 60 |
Updated: | 1/23/2019 |
Start Date: | March 23, 2018 |
End Date: | August 30, 2019 |
Contact: | Gloria Rodriguez, LPN |
Email: | g.rodriguez8@med.miami.edu |
Phone: | 305-243-8052 |
Specific Aims:
1. Establish in an open label clinical trial the tolerability and safety of various doses
of l-histidine and lodosyn that may increase levels of l-histidine and histamine in the
serum and cerebrospinal fluid (CSF).
2. Perform pharmacokinetic studies in serum and CSF of study subjects the levels of
l-histidine and histamine after treatment with various combination of l-histidine and
lodosyn.
3. Preliminary information will also be collected on the effects of this intervention on
alleviation of fatigue.
The findings from this study go beyond the effects of histamine on fatigue. If central
histamine can be increased by the strategy outlined above, a number of other vegetative
hypothalamic functions intricately associated with fatigue including sleep, cognition and
satiety need to be examined in MS patients in future studies.
1. Establish in an open label clinical trial the tolerability and safety of various doses
of l-histidine and lodosyn that may increase levels of l-histidine and histamine in the
serum and cerebrospinal fluid (CSF).
2. Perform pharmacokinetic studies in serum and CSF of study subjects the levels of
l-histidine and histamine after treatment with various combination of l-histidine and
lodosyn.
3. Preliminary information will also be collected on the effects of this intervention on
alleviation of fatigue.
The findings from this study go beyond the effects of histamine on fatigue. If central
histamine can be increased by the strategy outlined above, a number of other vegetative
hypothalamic functions intricately associated with fatigue including sleep, cognition and
satiety need to be examined in MS patients in future studies.
Inclusion Criteria for Healthy Volunteers:
1. Male or female subjects between the ages of 18 and 60 will be eligible.
2. Subjects should be in good physical health without history of chronic illness and
should be generally considered healthy.
3. Spouses or caregivers of patients with MS would be encouraged to participate.
Inclusion Criteria for Patients with Multiple Sclerosis (MS):
1. Patients with MS regardless of the disease type, who experience severe fatigue will be
eligible to participate.
2. Fatigue Severity Score of >/= 4.0 will qualify as long as all other inclusion /
exclusion criteria are met.
3. Established MS by McDonald Criteria - 2010 Revision (24). Relapse Remitting (RR) and
progressive forms of MS are eligible
4. Severe fatigue that has lasted greater than 6 months
5. Clinically stable on a current therapy with any Disease Modifying Therapy (DMT)
Exclusion Criteria for Healthy Volunteers:
1. Adults unable to give informed consent due to cognitive impairment or mental
disorders.
2. Children below the age of consent
3. Pregnant women
4. Prisoners
5. History of chronic disorders like hypertension, diabetes, hyperlipidemia, depression,
hypothyroidism etc. that require chronic treatment
6. Known chronic fatigue syndrome
7. Blood disorders or coagulopathy
8. Chronic allergies or history of asthma.
9. Using antihistamines, bronchodilators or H2 blockers for hyperacidity
10. Using medications for sleep, or known sleep disorders
11. Any medication or condition deemed unsuitable by the PI
Exclusion Criteria for Patients with Multiple Sclerosis (MS):
1. Adults unable to give informed consent due to cognitive impairment or mental
disorders.
2. Children below the age of consent
3. Pregnant women
4. Prisoners
5. Systemic disorders known to cause fatigue such as severe anemia, infections, chronic
systemic infectious or inflammatory disorders, including known autoimmune disorders.
6. Chronic fatigue syndrome
7. Hypothyroidism
8. Systemic malignancy
9. Undergoing chemotherapy
10. Depression
11. Sleep disorders including narcolepsy, excessive day-time sleep.
12. History of substance abuse
13. Excessive consumption of coffee or over-the-counter stimulants
14. Concomitant medications of amantadine, methylphenidate, amphetamines, pemoline,
barbiturates, tizanidine, Monoamine oxidase inhibitor (MAO) inhibitors,
benzodiazepines, barbiturates, tricyclic antidepressants, antihistamines, H2 blockers
for gastro-esophageal reflux disease (GERD), selective serotonin reuptake inhibitors
(SSRIs) and any other medication that in the opinion of the PI should be excluded.
15. Patients who were using modafinil for treatment of fatigues prior to the study may
participate but will be required to undergo a washout of 2 weeks prior to entry into
the trial.
We found this trial at
1
site
Miami, Florida 33124
(305) 284-2211
Principal Investigator: Kottil W Rammohan, M.D
Phone: 305-246-2279
University of Miami A private research university with more than 15,000 students from around the...
Click here to add this to my saved trials